Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue

Core Viewpoint - Karolinska Development AB is conducting a rights issue of series B shares amounting to approximately SEK 202.6 million, which has been approved by the Board of Directors and the extraordinary general meeting [2]. Group 1: Rights Issue Details - The rights issue is set to raise approximately SEK 202.6 million before transaction costs, as resolved by the Board on December 1, 2025, and approved on January 8, 2026 [2]. - An information document has been prepared in accordance with the Prospectus Regulation, detailing the terms and conditions of the rights issue, which has been registered with the Swedish Financial Supervisory Authority [3]. - The timetable for the rights issue includes trading in subscription rights from January 13 to January 22, 2026, and a subscription period from January 13 to January 27, 2026 [4]. Group 2: Advisory and Legal Support - Redeye AB is acting as the financial adviser, while Cirio Advokatbyrå AB serves as the legal adviser for the rights issue [5]. Group 3: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [7]. - The company aims to create and grow companies that advance medical innovations into commercial products, benefiting patients and providing returns to shareholders [8]. - Karolinska Development has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around top scientists supported by experienced management teams [9].